Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kissei Pharmaceutical And Wakamoto Pharmaceutical Co-Promote Salagen

This article was originally published in PharmAsia News

Executive Summary

Kissei Pharmaceutical and Wakamoto Pharmaecutical signed an agreement May 2 to co-promote Kissei's Salagen (pilocarpine), a drug used to treat dryness of the mouth and throat that may occur after radiation treatment for cancer of the head and neck, and to patients with Sjogren's syndrome. Kissei obtained the drug's exclusive development and marketing right in Japan from MGI Pharma, a subsidiary of Eisai. According to the agreement, Kissei and Wakamoto will promote the drug to assigned medical facilities, but Kissei will continue to solely handle manufacturing, marketing and distribution. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068657

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel